Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.
The NRG Oncology Semiannual Meeting takes place from February 15 to 17, 2024, and serves as a hub where clinicians and researchers can meet and collaborate on the latest findings and practices in the oncology field.
Pedro Barata, MD, MSc, FACP, genitourinary oncology and clinical researcher, highlights NRG as "one of the most cooperative groups out there" when it comes to providing a space for oncologists to discuss questions and problems.
Here, Barata, a member of the Young Investigators Committee and Genitourinary Committee, discusses the goals and importance of the semiannual meeting.
Transcription:
0:05 | NRG, it’s one of the most important cooperative groups out there. Basically, what that means is a number of physicians and researchers get together on a regular basis and put together and try to develop concepts that ultimately will help patients. We try to answer questions that are relevant to patients, in this case diagnosed with many cancers. It’s an organization [that] has, you know, actually has the ability to get together colleagues and experts from different specialties, including radiation oncology, urology, medical, oncology, imaging, etc. Their role in helping moving science forward, you know, for the treatment of cancer, it's super, super important and has been for a long time.
0:58 | I think NRG, it's organized the way we know it for 10 years in a row, and it has been played a very important role in the management of advanced tumors, across solid tumors, but their role in in in academic research, it's fantastic.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More